News

Ben Venue issues a voluntary patient level recall of Acetylcysteine Solution 10% due to glass particle in vial.

Conference sessions, keynote events, exhibits, and poster sessions cover different aspects of bioprocessing.

Ecolab's Shield Medicare division will now be called Ecolab Contamination Control.

Tandem Diabetes Care expands its voluntary recall of select lots of insulin cartridges used with t:slim insulin pump.

Innovative Medicines Initiative will develop novel antibiotics against gram-negative pathogens in a project called ENABLE.

Agilent Technologies and Cell Line Genetics will collaborate on services for regenerative medicine and cancer research.

Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.

New medicines in development include treatments for type 1 and type 2 diabetes.

EMA releases an update on its flu vaccine guidance.

Cobra Biologics' GMP Compliance Certification has been extended to include QC testing.

Shimadzu's new Solution Center features additional research space.

Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.

Shimadzu's new Solution Center features additional research space.

Mylan Pharmaceuticals launches Hertraz, the world's first trastuzumab biosimilar in India.

Aesica appoints Ian Muir to the newly created position of commercial managing director.

Sartorius appoints Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division.

FDA plans to issue a number of new guidances in 2014 that will address drug development and manufacturing practices.

NIH, 10 biopharmaceutical companies, and several nonprofit organizations form a partnership to develop new treatments earlier for Alzheimer's, type 2 diabetes, and autoimmune disorders.

Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.

Edison and DSP partner to develop drugs targeting cellular energy metabolism.

International Society for Pharmaceutical Engineering will continue strategic plan initiated by Nancy Berg; search begins for replacement.

EMD Millipore's expands its Emprove raw materials portfolio to include 400 products.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

EMA's guidance focuses on the use of pharmacogenomics to improve drug safety monitoring.

NCI launches trial to assess the utility of genetic sequencing to improve patient outcomes.

Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.

FDA adds Ranbaxy's Toansa, India facility to existing consent decree, prohibiting distribution of APIs from that location